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Abstract
Background: The ability to respond to anti-growth signals is critical to maintain tissue homeostasis and loss of this negative
growth control safeguard is considered a hallmark of cancer. Negative growth regulation generally occurs during the G0/G1
phase of the cell cycle, yet the redundancy and complexity among components of this regulatory network has made it
difficult to discern how negative growth cues protect cells from aberrant proliferation.
Methodology/Principal Findings: The retinoblastoma protein (pRB) acts as the final barrier to prevent cells from entering
into the cell cycle. By introducing subtle changes in the endogenous mouse Rb1 gene (Rb1DL), we have previously shown
that interactions at the LXCXE binding cleft are necessary for the proper response to anti-growth signals such as DNA
damage and TGF-b, with minimal effects on overall development. This disrupts the balance of pro- and anti-growth signals
in mammary epithelium of Rb1DL/DL mice. Here we show that Rb1DL/DL mice are more prone to mammary tumors in the Wapp53R172H transgenic background indicating that negative growth regulation is important for tumor suppression in these
mice. In contrast, the same defect in anti-growth control has no impact on Neu-induced mammary tumorigenesis.
Conclusions/Significance: Our work demonstrates that negative growth control by pRB acts as a crucial barrier against
oncogenic transformation. Strikingly, our data also reveals that this tumor suppressive effect is context-dependent.
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disruption of an individual CKI, such as p21Cip1, can result in
deregulated proliferation despite signals from negative growth
regulatory stimuli such as DNA damage [6,7]. However, negative
growth regulators such as TGF-b are capable of inducing a cell
cycle arrest in the absence of any one of these CKI proteins
[8,9,10,11]. Furthermore, ablation of individual CKI genes in
mice has no effect on viability and is accompanied by surprisingly
few developmental abnormalities. Interestingly, each knockout
mouse strain develops tumors in a specific subset of tissues, but
none of these mice develop mammary tumors [11,12,13,14,
15,16,17,18]. In fact, pRB itself was previously considered
dispensable for mammary development [19]. This is surprising
because pRB pathway components such as cyclin D1 are
commonly amplified, and pRB itself is sometimes lost in human
breast cancers and these are direct targets of CKI regulation
[20,21,22,23,24]. Thus, even though the current body of literature
suggests that anti-growth effects greatly influence mammary
epithelial cells [1], mouse models reveal layers of complexity that
make it challenging to understand how negative growth responses
protect mammary epithelial cells from aberrant proliferation and
ultimately tumorigenesis.
Activation of pRB maintains cells in G0/G1 and prevents
inappropriate cell cycle entry [3]. Breast epithelial cells frequently

Introduction
Maintenance of tissue homeostasis is a tightly regulated process
and the loss of responsiveness to negative growth signals can alter
this delicate balance, leading to cancer [1]. This is especially
evident in the breast, where epithelial cells undergo cycles of
quiescence, proliferation, differentiation, and apoptosis during the
menstrual cycle and as a result of pregnancy [2]. Tight negative
growth control of the mammary epithelial compartment is crucial,
and disruption of the balance between mitogenic and anti-growth
signals can leave this tissue susceptible to the formation of cancer
[3,4]. Therefore, delineating how negative growth control of
breast epithelial cells is lost during tumor formation is essential to
understand the pathogenesis of breast cancer.
Insensitivity to negative growth signals is considered a hallmark
of cancer cells [1]. This means that the mechanism that conveys
growth inhibiting signals from DNA damage or transforming
growth factor b (TGF-b) to the cell cycle machinery is universally
disrupted. In general, growth inhibiting signals arrest the cell cycle
by blocking cyclin dependent kinase (CDK) activity through the
actions of cyclin dependent kinase inhibitors (CKIs) such as
p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 [3,5]. This in turn
activates the retinoblastoma protein (pRB). In cell culture,
PLoS ONE | www.plosone.org
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oncogenic allele of Ras (pLXSN dn p53/RasV12) [32]. Expression
of these oncogenes resulted in a greater frequency of colonies in
Rb1DL/DL MEFs compared with controls (Fig. 1a, b). Furthermore,
many Rb1DL/DL colonies were also larger than control colonies
(Fig. 1a), suggesting that cells lacking pRB-LXCXE interactions
were able to transform earlier. Since the effect of the Rb1DL
mutation is exerted after only a few cell divisions, we interpret this
phenotype to be caused by a defect in negative growth control
rather than genome instability, which can also result from
expression of the Rb1DL allele [28,29]. This provided proof of
principle that pRB-LXCXE-dependent anti-growth effects can
protect cells from oncogenic transformation.
To validate that pRB-LXCXE interactions can exert a tumor
suppressive effect in the mammary gland, we crossed our mice into
the Wap-p53R172H background. Wap-p53R172H is a dominant
negative form of p53 driven by the whey acidic protein promoter,
which is expressed in the mammary gland during pregnancy and
lactation. We bred cohorts of Wap-p53R172H; Rb1+/+ and Wapp53R172H; Rb1DL/DL females through five rounds of pregnancy in
order to induce transgene expression (Fig. 2a). Since Rb1DL/DL
females are frequently unable to nurse their pups [26], all live pups
were removed two days after birth to ensure consistent timing of

respond to anti-growth signals from DNA damage, exogenous
growth factors like TGF-b, and other cellular stresses. All of these
serve to activate pRB and arrest proliferation [25]. Using a knockin mouse model with a discrete defect in the pocket domain of Rb1
(Rb1DL), we have reported the remarkable discovery that pRB uses
interactions with LXCXE-motif-containing proteins almost exclusively for growth arrest in response to stressful negative growth
stimuli, and this mechanism is largely dispensable for cell cycle
control in development allowing us to obtain viable animals with
this defect [26,27]. The lone circumstance in development where
pRB interactions with LXCXE containing proteins, such as
histone deacetylases, are critical is in mammary epithelium. In this
tissue, ductal morphology and branching are normal, but there is
mild hyperplasia of the luminal cell compartment [26]. Our data
indicates that, the Rb1DL mutation results in an inability to silence
transcription of E2F target genes and renders cells insensitive to
anti-growth signals, including TGF-b, DNA damage, and other
senescence cues [26,27]. Furthermore, cells from these mice fail to
induce growth arrest in response to ectopic expression of the CKI
proteins p16Ink4a and p21Cip1 [26]. This suggests that there are
likely many stress-induced negative growth signals to which cells
from these mice are uniquely resistant. Since pRB-dependent
negative growth control is dramatically reduced in the mammary
glands of Rb1DL mice, but viability and overall development are
normal, these animals provide a unique opportunity to examine
the impact of negative growth signals in suppressing mammary
cancer.
In order to understand the role of pRB LXCXE-dependent
negative growth control during mammary tumorigenesis, we have
crossed our mice with a Wap-p53R172H transgenic strain. Wapp53R172H; Rb1DL/DL females developed mammary tumors more
frequently and at a significantly younger age than control mice,
while showing no differences in histopathological characteristics or
metastasis. This strongly suggests that loss of negative growth
regulation in this model exacerbates cancer development at a very
early stage. In contrast, co-expression of Neu and Rb1DL did not
accelerate mammary tumor initiation, progression, or metastatic
dissemination. Surprisingly, the contrasting data between the two
transgenic mammary tumor models indicates that failure to
respond to negative growth signals by pRB affects cancer
incidence in a context-dependent manner.

Results
pRB-LXCXE interactions act as an initial barrier to tumor
formation
Our lab has previously generated a knock-in mouse model
(Rb1DL) to disrupt the LXCXE binding cleft on the retinoblastoma
tumor suppressor protein [28]. Loss of LXCXE-dependent
interactions, between pRB and enzymes such as histone
deacetylases, disrupts negative growth control in the mammary
gland during development. This leads to hyperplasia of the ductal
epithelium that is ubiquitously detectable in virgin animals
between four and 16 weeks of age [26]. The Rb1DL mutation
alone does not lead to spontaneous mammary cancer, perhaps
because this mutation doesn’t increase the cellular proliferation
rate, but alters the response to negative growth cues [26,29]. Since
hyperplasia of ductal epithelia is considered a risk factor for
human breast cancer [30,31], we postulated that the Rb1DL
mutation would exacerbate cancer pathogenesis when combined
with other oncogenic changes that provide a proliferative signal.
To explore this possibility, we first performed a soft agar colony
assay using Rb1+/+ and Rb1DL/DL mouse embryonic fibroblasts
(MEFs) expressing a dominant negative form of p53 and an
PLoS ONE | www.plosone.org

Figure 1. The Rb1DL mutation confers sensitivity to oncogenic
transformation. A) MEF cells corresponding to the indicated
genotypes were transduced with retroviruses expressing dominant
negative (dn) p53 and RasV12 and plated in soft agar to allow colonies to
form. Photomicrographs were taken after a two-week growth period.
Number in the bottom right corner of each photomicrographs indicate
the number of colonies that contained 5 or more cells. Scale: 200 mm. B)
The percentage of wild type and mutant cells that transformed and
grew into a colony was calculated from five randomly photographed
microscopic images. A cell was counted as transformed if it formed a
colony whose size appeared to be at least 5 cells. * indicates a
statistically significant difference (Student’s t test; P,0.005). Error bars
indicate one standard deviation from the mean for at least three
replicates.
doi:10.1371/journal.pone.0016434.g001

2

February 2011 | Volume 6 | Issue 2 | e16434

pRB-Dependent Negative Growth Response in Cancer

Figure 2. pRB-LXCXE interactions protect against tumor formation caused by the Wap-p53R172H transgene. A) Experimental outline for
the Wap-p53R172H tumor study. Mice were bred through five rounds of pregnancy (thin arrows) to transiently induce p53R172H expression within the
mammary gland. After the fifth pregnancy, males were removed and females were palpated weekly to monitor tumor formation. Median tumor-free
survival for each genotype is marked with the colored arrows. B) Representative H&E stained paraffin sections from tumors harvested from Wapp53R172H; Rb1+/+ and Wap-p53R172H; Rb1DL/DL mice. Arrows indicate mitotic figures that are shown in the inset. Scale: 50 mm. C) The mitotic index for
Wap-p53R172H; Rb1+/+ and Wap-p53R172H; Rb1DL/DL mice is indicated, along with the average mitotic index for each genotype. Values were derived by
quantifying the number of mitotic figures in five random fields of view for each mouse. D) Kaplan-Meier graph of mammary tumorigenesis is shown
for Wap-p53R172H; Rb1+/+ and Wap-p53R172H; Rb1DL/DL females (log rank test; P = 0.0238). Values in brackets indicate the number of mice that developed
tumors. E) Carmine Red–stained mammary whole mounts from tumor-free glands in mice that had mammary tumors are shown for both genotypes
in the Wap-p53R172H background. Arrows indicate hyperplastic nodules and LN indicates lymph nodes. Scale: 2 mm. The number of hyperplastic
nodules in each whole mount section was also quantified for each genotype along with the average number of hyperplastic nodules.
doi:10.1371/journal.pone.0016434.g002

transgene expression between genotypes. Wap-p53R172H expression
leads to genomic instability [33,34], so we reasoned that
expression of p53R172H during pregnancy and lactation would
create random mutations. We expected that some of these
mutations would drive tumorigenesis later, after the transgene
was turned off, and this would allow us to assess how a diminished

PLoS ONE | www.plosone.org

response to negative growth regulators affects mammary tumorigenesis. Both Wap-p53R172H; Rb1+/+ and Wap-p53R172H; Rb1DL/DL
females developed high grade mammary adenocarcinomas,
characterized by high cytological variability. Many cells exhibited
large cellular and nuclear size which is comparable to other studies
using Wap-p53R172H mice, indicating that the transgene was active
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in both genotypes (Fig. 2b) [33,34]. Furthermore, tumors from
both genotypes displayed high but comparable rates of mitosis and
similar rates of tumor growth (Fig. 2c and data not shown),
demonstrating that the rate of proliferation was similar for Wapp53R172H; Rb1+/+ and Wap-p53R172H; Rb1DL/DL tumors.
While mice from both genotypes developed similar types of
tumors, we found an increased frequency of tumor formation in Wapp53R172H; Rb1DL/DL females. 63.6% of Wap-p53R172H; Rb1DL/DL
females compared to 44.4% of Wap-p53R172H; Rb1+/+ females
developed tumors over the course of the study. Importantly, loss of
pRB-LXCXE interactions in the Wap-p53R172H background also
resulted in earlier tumor onset as detected by mammary palpation
(Fig. 2d) (Log rank test, P = 0.0238). Like the data from our soft agar
colony assay, this suggests that pRB-dependent anti-growth control
can act as a barrier to tumor initiation, and when it is lost in Rb1DL/DL
females Wap-p53R172H can then drive tumour progression. To
explore this concept further, we examined tumor-free mammary
glands from our tumor-burdened mice. Some mammary glands had
extensive lobuloalveolar development, preventing an assessment of
abnormal proliferation by whole mount staining. However, we
examined glands where tumors were not palpable among the
remaining necropsied animals, and discovered that there was a small
increase in the number of hyperplastic lesions in the Wap-p53R172H;
Rb1DL/DL mice (Fig. 2e). Together with the increased frequency of
tumors and shortened timing of tumor onset in Wap-p53R172H;
Rb1DL/DL females, these data indicate that pRB-dependent antigrowth control acts as an initial barrier to tumor formation in the
mammary gland. In addition, both Wap-p53R172H; Rb1+/+ and Wapp53R172H; Rb1DL/DL tumors were able to metastasize to the lungs, and
there were no major differences in the appearance of the metastases,
or the number, or size of these metastases (Fig. 3). This is distinct from
previous reports demonstrating that loss of pRB-mediated genomic
stability leads to more aggressive tumors and increased metastasis
[29]. Because the frequency of cancer incidence and age of onset are
exacerbated by the Rb1DL mutation, but aspects of progression such
as proliferation rate and metastasis are indistinguishable from
controls, we conclude that reduced responsiveness to negative growth
signals likely functions as a barrier to tumor initiation at a very early
stage in cancer pathogenesis.

Figure 3. Metastases form in the Wap-p53R172H; Rb1+/+ and Wapp53R172H; Rb1DL/DL mice. A) Representative H&E stained paraffin
sections of lungs harvested from tumor-burdened mice of each
genotype. M denotes metastasis, and L denotes neighboring lung
tissue. Scale: 100 mm. B) The surface area (SA) occupied by lung
metastases relative to the total lung area in tissue sections was
quantified for mice from each genotype along with the average SA.
Values in brackets indicate the number of mice that developed
metastases and { indicates a female that developed metastases to both
the lung and spleen.
doi:10.1371/journal.pone.0016434.g003

attributed to TGF-b-induced cell cycle arrest, although this aspect
of its signaling has not been testable in isolation before now. For
these reasons Neu mice offer a relatively well characterized system
in which to determine how important negative growth signalling is
in opposing mammary cancer formation.
Since TGF-b is a key negative regulator of proliferation in the
mammary epithelial compartment and induces a G1 arrest in a
pRB-LXCXE-dependent manner [26], we next wanted to
characterize the Neu; Rb1DL/DL genotype to ensure that this
experimental system would allow us to address the role of negative
growth responses during tumorigenesis as we expected. To this
end we tested Rb1+/+, Rb1DL/DL, and Rb1DL/+ mammary epithelial
cells (MECs) for their ability to respond to TGF-b–induced G1
arrest (Fig. 4a). This confirmed our previous results that TGF-b’s
cytostatic response is vastly diminished in Rb1DL/DL cells [26].
Surprisingly, Rb1DL/+ MECs have a similar defect in TGF-b
growth control indicating that mutation of only one copy of Rb1 is
sufficient to abrogate its arrest mechanism. Consistent with this
observation, examination of mammary epithelia in Rb1DL/+ virgin
female mice revealed they have a similar degree of hyperplasia as
we have previously reported for Rb1DL/DL mice (Fig. 4b) [26]. The
proto-oncogenic Neu in these young mice needs to be activated by
a deletion in its extracellular domain, so the growth signals that
will drive cancer formation are not evident at this early stage [39].

Retinoblastoma-dependent negative growth effects on
tumorigenesis are context-dependent
The advantage of the Wap-p53R172H model is that it introduces
random mutations and this creates a selection for ones that can
cooperate with defects found in Rb1DL/DL mice. However, this also
prevents us from knowing what the initiating oncogenic mutations
were and how they normally engage negative growth responses
that activate a pRB-LXCXE-dependent arrest. For this reason we
also used a transgenic line that expresses a dominantly acting
oncogene so that the origin of oncogenesis would be known. To
determine how pRB-dependent responses to negative growth
signals affect mammary tumorigenesis in this context, we crossed
our mice into the Tg(MMTVneu)202Mul (herein referred to as Neu)
background, where expression of the rat proto-oncogene Neu is
driven by the MMTV promoter. These mice normally develop
focal mammary tumors with a high rate of metastasis to the lung
[35]. We chose this transgenic line because Neu is known to
activate the Ras pathway [36] and our data in Figure 1 indicates
that pRB-dependent growth arrest opposes it. Furthermore,
expression of activated Neu in mice with disrupted TGF-b
signaling results in reduced tumor latency [37]. Conversely, when
crossed to mice that overexpress TGF-b or a constitutively active
TGF-b receptor, primary tumor formation is delayed or tumor
growth is slowed [37,38]. This anti-tumor effect is commonly
PLoS ONE | www.plosone.org
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mutant genotypes was also relatively unchanged from wild type
(85.7% for Rb1DL/DL and 77.4% for Rb1DL/+ vs. 90% for wild
type).
This result suggests that negative growth regulatory signals
that depend on pRB do not significantly influence cancer
pathogenesis in Neu transgenic mice. Because this was unexpected, we also investigated other tumor characteristics to determine
if the Rb1 mutant genotypes altered the tumor type of these mice
in such a way that the direct comparison in Fig. 5a is misleading.
To this end, we classified the tumors histologically and
discovered that they all fit the characteristics of solid or acinar
carcinomas that have been reported previously for Neu mice,
indicating that transgene function was not altered in the different
genotypes (Fig. 5b) [40]. Our expectation from the Wap-p53R172H
cross is that negative growth responses are most important at the
initiation step. However, Muraoka et al. found that overexpression of TGF-b did not affect tumor latency of Neu mice, but
instead reduced tumor proliferation [38]. For this reason we
measured the number of mitotic figures in five randomly selected
microscopic fields for each tumor as a means to compare
proliferation and this revealed no significant differences (Fig. 5c).
Furthermore, there were no significant differences in the final
tumor volume (Fig. 5c). Lastly we investigated unaffected
mammary glands from tumor-burdened animals for evidence of
non-malignant nodules by whole mount preparations. Again,
there were no statistically significant differences between the
three Rb1 genotypes and if anything there was a trend toward
fewer nodules in mice bearing the Rb1DL mutation (Fig. 5d).
These findings are in stark contrast to those for the Wap-p53R172H
cross, where there was an earlier tumor onset in Wap-p53R172H;
Rb1DL/DL females and slightly more hyperplastic nodules (Fig. 2a,
2d, 2e). Together, these data indicate that loss of pRB-dependent
anti-growth control exacerbates Wap-p53R172H–dependent tumor formation, but leaves Neu-driven tumorigenesis unaltered.
This indicates that during cancer formation, the response to antigrowth signals by pRB is context-dependent.
In an effort to better relate the combination of the Wapp53R172H and Neu transgenes with our Rb1 mutant, we also
investigated metastasis in Neu; Rb1+/+, Neu; Rb1DL/+, and Neu;
Rb1DL/DL female mice. This revealed that the number of lung
surface metastases that formed during the 60 day period from
initial palpation to euthanasia were similar (Fig. 6a). Furthermore,
these metastatic lesions occupied a similar proportion of tissue
volume when quantified microscopically in lung sections (Fig. 6b).
Lastly, there were no apparent differences in histology between
metastases from the respective genotypes (Fig. 6c). From these
experiments it is clear that the Rb1DL allele does not enhance the
metastatic potential of mammary tumors whether they form in the
Neu or Wap-p53R172H backgrounds.
This reveals that pRB can confer responsiveness to negative
growth signals that limit p53R172H tumorigenic effects. Surprisingly, this aspect of pRB function does not affect Neu-driven
oncogenesis. Unexpectedly, these experiments reveal that loss of
pRB-dependent negative growth responsiveness does not ubiquitously contribute to cancer formation in the mammary gland.

Figure 4. Defective TGF-b proliferative control in Rb1DL/DL and
Rb1DL/+ mice. A) Rb1+/+, Rb1DL/+, and Rb1DL/DL mammary epithelial cells
were treated with TGF-b1 and pulse labeled with BrdU 24 hrs later. The
percentage of cells incorporating BrdU was measured by immunofluorescence microscopy. The fold decrease in proliferation between
treated and untreated parallel cultures was determined and the average
of three independent experiments is shown. * indicates a statistically
significant difference (Student’s t test; P,0.05). Error bars indicate one
standard deviation from the mean. B) H&E staining of paraffin sections
of Rb1+/+, Rb1DL/+, and Rb1DL/DL mammary tissue from 8 week old mice.
Each image displays a representative cross section of ducts. The table
below displays the proportion of hyperplastic (hp) ducts found in
Rb1+/+, Rb1DL/+, and Rb1DL/DL mammary glands. Proportions were
compared between genotypes using a chi-square test. Scale: 100 mm.
{ denotes previously published data that has been provided for
comparison purposes.
doi:10.1371/journal.pone.0016434.g004

Because of the defective response to negative growth signals caused
by the Rb1DL mutation, these mice create an ideal opportunity to
assess how an oncogenic growth signal is opposed. Importantly,
this can be determined by comparing Neu transgenic mice with
wild type Rb1 to either Rb1DL/+ or Rb1DL/DL animals.
To assess the importance of pRB-dependent negative growth
control in suppression of primary tumor formation and growth, we
followed cohorts of Neu; Rb1+/+, Neu; Rb1DL/+ and Neu; Rb1DL/DL
females throughout their natural lives and palpated them weekly to
determine the onset of mammary tumor formation. Unfortunately,
the long latency before tumor formation resulted in excessive
grooming in many of our mice and the need to euthanize them
before palpable tumors formed. This was particularly true of the
Neu; Rb1DL/DL mice. However, the Neu; Rb1DL/+ animals have a
similar response to TGF-b, indicating that they offer the same
insight into how negative growth signals impact tumorigenesis in
this transgenic model. In contrast to the Wap-p53R172H; Rb1DL/DL
mice, there was no difference in tumor latency between the
remaining Neu; Rb1DL/DL females and females from the other two
genotypes (Fig. 5a). The frequency of tumorigenesis in the Rb1
PLoS ONE | www.plosone.org

Discussion
Using two transgenic mouse models of breast cancer, we have
examined the importance of pRB-LXCXE interactions during
cancer formation and progression. Our work has revealed that
LXCXE-dependent anti-growth control can act as a barrier to
oncogenic transformation in the mammary gland. Surprisingly,
the Rb1DL mutation exacerbated Wap-p53R172H-induced tumor
5
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Figure 5. Loss of pRB-LXCXE interactions does not affect Neu-driven tumorigenesis. A) Onset of mammary tumorigenesis is shown for the
indicated genotypes (log rank test; P = 0.6788). Values in brackets indicate the number of mice that developed tumors. B) Representative H&E stained
paraffin sections from tumors harvested from Neu; Rb1+/+, Neu; Rb1DL/+, and Neu; Rb1DL/DL mice 60 days after initial tumor palpation. Arrows indicate
mitotic figures that are shown in the inset. Scale: 50 mm. C) The mitotic index and final tumor volumes for Neu; Rb1+/+, Neu; Rb1DL/+, and Neu; Rb1DL/DL
mice are indicated, along with the average values for each genotype. Mitotic indices were derived by quantifying the number of mitotic figures in five
random fields of view for each mouse. Final tumor volume was calculated using the formula V = 0.526W26L. D) Carmine Red–stained mammary
whole mounts from tumor-free glands in mice that had mammary tumors are shown for the given genotypes. Arrows indicate hyperplastic nodules
and LN indicates lymph nodes. Scale: 2 mm. The number of hyperplastic nodules in each whole mount section was also quantified for each genotype
along with the average number of hyperplastic nodules.
doi:10.1371/journal.pone.0016434.g005

controls [29]. Furthermore, they also exhibited increased metastasis
[29]. In contrast, we saw no change in tumor size, proliferation, or
metastasis in Wap-p53R172H; Rb1DL/DL mice. The increase in tumor
penetrance and earlier onset in the Wap-p53R172H; Rb1DL/DL
background are more consistent with an inability to induce a
growth arrest. We posit that pRB acts as a braking mechanism,
protecting the cell from aberrant growth in response to stresses in
this transgenic model. Mutations to the LXCXE binding cleft
disrupt this braking system, leaving cells vulnerable to oncogenic
stimuli, such as those generated in the Wap-p53R172H model.

formation, while having no effect in the Neu transgenic
background.
The retinoblastoma protein has several important roles in the cell
including induction of a cell cycle arrest in response to various
stresses, as well as maintaining genome stability [26,27,29]. While it
is possible that the enhanced tumor phenotype observed here is the
result of increased genomic instability, we do not consider this a
likely possibility for several reasons. Recent work demonstrated that
loss of pRB-mediated genome integrity manifests as more aggressive
tumors characterized by altered histopathology compared to

PLoS ONE | www.plosone.org
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size and length of G1 and S phases are similar to wild type cells,
indicating that this Rb1 mutant is phenotypically distinct from the
increased rate of proliferation found in Rb12/2 cells [28]. Instead,
Rb1DL/DL cells have a defect in inducing cell cycle arrest in
response to anti-growth signals (Fig. 4a) [26,27]. Second, in both
the Wap-p53R172H and Neu crosses, the rates of proliferation were
comparable between control tumors and those lacking pRBLXCXE interactions (Fig. 2c and Fig. 5c). In contrast, the median
age of tumor onset was significantly lower for Wap-p53R172H;
Rb1DL/DL females, compared to control mice (Fig. 2a, 2d).
Similarly, only Wap-p53R172H; Rb1DL/DL tumor-free mammary
glands displayed an increase in hyperplastic nodule formation.
This suggests that the Rb1DL/DL mutation impacts tumorigenesis at
an early stage, rather than increasing proliferation in existing
tumors. Taken together, we interpret these findings to indicate
that pRB responds to anti-growth signals to act as a barrier to
initial tumor formation by inducing cell cycle arrest; loss of this
anti-growth pathway leaves mammary epithelial cells vulnerable to
oncogenic transformation caused by p53R172H.
Unresponsiveness to negative growth signals is described as a
hallmark of cancer, implying a ubiquitous need for it to be
eliminated during tumorigenesis [1]. There is little evidence of
how these signals are generated and when they act to block
aberrant proliferation. The evidence of their importance is largely
implied by the frequency of their loss in cell cultures generated
from tumors. Our genetic approach is a first step to gaining better
insight into this mechanism. Our data from studying Neu-induced
tumorigenesis implies that negative growth signals may be lost with
no apparent effect on cancer incidence. However, comparing the
two tumor models used here may be instructive in narrowing
down the possibilities. Both Wap-p53R172H and Neu (line 202)
require accompanying or sporadic mutations in the transgene to
initiate cancer [34,39]. The Neu transgene requires the deletion of
a small portion of the ectodomain to be become activate and drive
cancer formation. This mechanism has been shown to be
consistent between individual Neu tumors as similar deletions are
generated each time. The resulting activated Neu receptors have
relatively weak transforming activity in comparison with the
original V664E mutant allele [39]. For this reason the relative
strength of the oncogenic signal may be an important factor. This
is consistent with mammary tumors in Wap-p53R172H; Rb1DL/DL
mice having incomplete penetrance; some animals may not
acquire sufficiently strong mutations. In addition, mitogenic
signals are known to elicit a negative growth response from
TGF-b in mammary epithelium [41]. For these reasons the
strength of oncogenic growth signal is likely an important cue in
determining if a negative growth arrest mechanism will need to be
overcome during tumor formation. Future experiments will need
to be designed to address this possibility.
Understanding the context in which the response to negative
growth signals is a key tumor suppressor mechanism is a
challenging new question. However, determining what factors
influence context in vivo will greatly influence our understanding of
negative growth control in cancer, and will undoubtedly impact
the classification and treatment of this disease in the future.

Figure 6. Loss of pRB-LXCXE interactions does not affect
metastatic potential in Neu mice. A) The number of lung surface
metastases (LSM) was quantified for individual mice and plotted along
with the average number of LSM per genotype. { indicates lungs with
.59 LSM and { indicates a lung where each of the two metastases
encompassed an entire lobe. B) The SA occupied by lung metastases
relative to the total lung area in tissue sections was quantified for mice
from each genotype along with the average SA for each genotype. C)
Representative H&E stained paraffin sections of lungs from tumorburdened mice are shown for each genotype. Scale: 100 mm.
doi:10.1371/journal.pone.0016434.g006

The precise pRB LXCXE-dependent anti-growth mechanism
that protects against Wap-p53R172H driven tumors is unclear since
mutant p53 acts as a generator of mutations that drive
tumorigenesis almost a year after the transgene has been silenced.
However, the exact source of anti-growth signals that fail to be
received in Wap-p53R172H; Rb1DL/DL mice is not the key question;
rather, the Rb1DL mutation allows us to determine the circumstances when the response to negative growth signals are most
important. We interpret our data to indicate that pRB responds to
these signals to oppose oncogenic transformation in mammary
epithelial cells at an early stage in tumorigenesis, before tumors
become palpable. Several lines of evidence support this conclusion.
First, prior analysis of Rb1DL/DL fibroblasts demonstrates that cell
PLoS ONE | www.plosone.org

Materials and Methods
Mouse strains
The Rb1DL mouse strain has been described previously [28].
Analyses of Rb1DL/DL mice were performed on a mixed 129/B6
background. Wap-p53R172H mice were obtained from the Mouse
Models of Human Cancer Consortium on an FVB background.
These mice express the p53R172H mutation driven by the whey
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acidic protein promoter [33]. These mice were bred to the Rb1DL
mutation, creating a mixed 129/B6/FVB genetic background.
Wap-p53R172H; Rb1+/+ and Wap- p53R172H; Rb1DL/DL females were
bred through five or six rounds of pregnancy to induce expression
of p53R172H. Live pups were removed at P2 to allow equivalent
timing of transgene expression between genotypes. Tg
(MMTVneu)202Mul (herein called Neu) mice express the wild type
form of the rat Neu oncogene driven by the murine mammary tumor
virus promoter (MMTV) [35]. These mice were obtained from
Jackson Labs on an FVB background and were bred to the Rb1DL
mutation, creating a mixed 129/B6/FVB genetic background.
Genotyping methods and PCR primers were provided by the
suppliers, or are as outlined by Isaac, et al. [28]. All animals were
housed and handled as approved by the UWO animal use
subcommittee (protocol 2007-058) and CCAC guidelines.

burdened mice were removed, mounted on glass slides, and
stained with Carmine Red using standard techniques.

Primary cell culture assays
Mammary epithelial cells were harvested and cultured as
previously described [26,42]. Cell culture experiments were
carried out on passage 1 or 2 MECs. TGF-b1 growth inhibition
assays were performed as previously described [26].

Soft Agar Colony Formation Assay
Rb1+/+ and Rb1DL/DL MEFs were retrovirally transfected with
the pLXSN dominant negative (dn) p53/RasV12 virus as
previously described [32,43]. Infected cells were then grown in
soft agar according to standard protocols [44]. Cells were allowed
to grow for 2 weeks, at which time colonies were photographed
and counted. The cut-off for scoring a colony as transformed was
that its size needed to correspond with the volume of at least 5 cells
(as judged by neighboring single cells). In this way we were
confident that these colonies represented multiple cell divisions.

Histology and mammary whole mounts
Full necropsies were performed on tumor-bearing animals after
60 days or at the time of euthanasia. Mammary tumors, lung
tissues, and any other tissues that appeared abnormal were fixed in
formalin and sectioned as previously described [26]. The mitotic
indices were manually counted in 5 high-power fields of view
(4006) for mammary tumors from each genotype. Lung
metastases were identified by gross morphological analysis (surface
metastases) and microscopic analysis (micrometastases). Percent
metastatic surface area (SA) was calculated by measuring the total
two dimensional area occupied by lung metastases in five
hematoxylin and eosin (H&E) stained lung sections, divided by
the total area of the lung in these sections using Volocity 4 software
(Perkin Elmer, Waltham, MA). Analysis of hyperplasia in H&E
stained sections of Rb1DL/+ mammary glands, as well as Neu
expressing mammary glands, was as described before [26]. For
whole-mount analysis, unaffected mammary glands from tumor-
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